On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Research entry: inclusion is for identification, not approval or a recommendation to use it. Verify the exact product and current US status with a pharmacist.
What the evidence shows
A different preparation
The cited CJC-1295 trials studied the long-acting analog. They do not establish that a product sold as “no DAC” has the same effects or safety. [1]
What a hormone study cannot establish
The long-acting study measured GH and IGF-1 responses. Even for that compound, it was not a trial of muscle growth or better sleep. For a differently identified no-DAC preparation, both identity and direct clinical evidence must be checked. [1]
What remains unknown
The exact molecule, formulation, and clinical evidence need confirmation. This guide does not establish sleep or body-composition benefits.
Safety
Do not assume equivalence
CJC-1295 safety information cannot establish safety for a different preparation. [2]
Naming ambiguity matters
Do not use the published long-acting CJC-1295 half-life, preparation, or study schedule as instructions for a no-DAC product. The linked study is provided to explain the distinction, not to claim equivalence. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Why does the guide discuss a different CJC product?
Because confusing those names leads to unsupported conclusions. The study is explicitly labeled as evidence for the long-acting analog and does not validate no-DAC claims.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults2006 · randomized human trials · PMID 16352683
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · safety information · accessed September 2026
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.